Cantor Fitzgerald Analysts Lower Earnings Estimates for ATXS

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Astria Therapeutics in a report issued on Wednesday, May 14th. Cantor Fitzgerald analyst S. Seedhouse now expects that the biotechnology company will earn ($2.38) per share for the year, down from their previous forecast of ($1.98). Cantor Fitzgerald currently has a “Overweight” rating and a $47.00 target price on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.65) per share.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.10).

Several other brokerages also recently weighed in on ATXS. Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Friday, January 31st. JMP Securities started coverage on shares of Astria Therapeutics in a report on Friday, January 31st. They issued an “outperform” rating and a $26.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a report on Tuesday, March 11th. Finally, Wedbush restated an “outperform” rating and issued a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $30.00.

Astria Therapeutics Stock Down 0.8%

ATXS stock opened at $3.96 on Friday. The business’s 50-day moving average price is $5.01 and its 200-day moving average price is $7.36. The stock has a market cap of $223.48 million, a P/E ratio of -1.89 and a beta of 0.45. Astria Therapeutics has a twelve month low of $3.56 and a twelve month high of $12.92.

Institutional Investors Weigh In On Astria Therapeutics

Hedge funds have recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new stake in Astria Therapeutics in the 4th quarter worth approximately $41,000. Tower Research Capital LLC TRC grew its holdings in shares of Astria Therapeutics by 109.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 2,766 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in Astria Therapeutics in the fourth quarter worth $50,000. Virtus ETF Advisers LLC bought a new stake in Astria Therapeutics in the fourth quarter worth $65,000. Finally, GAMMA Investing LLC raised its stake in Astria Therapeutics by 1,127.4% during the first quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 7,971 shares in the last quarter. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.